» Articles » PMID: 39076412

Medical Cannabis Patients Under the Age of 21 in the United States: Description of Demographics and Conditions from a Large Patient Database, 2019-2023

Overview
Publisher Dove Medical Press
Date 2024 Jul 30
PMID 39076412
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Existing research on medical cannabis patients has often overlooked those younger than 21. This study aimed to detail the frequency and rate of pediatric medical cannabis patients in the US using a large patient database.

Methods: Utilizing Leafwell Patient Database data from 2019 to mid-2023, we described demographics and qualifying conditions, employing descriptive statistics and χ2 tests to discern differences between minors (0-17 years) and young adults (18-20 years). We calculated rates per 100,000 population by state.

Results: Analyzing 13,855 patients, 5.7% were minors and 94.3% were young adults. Anxiety emerged as the primary self-reported condition for both groups, yet differences were seen for other conditions. Differences were observed by race/ethnicity, health insurance status, residency in adult-use states, and number of reported conditions. Notably, both groups reported a similar average number of conditions.

Conclusion: This study underscores demographic distinctions between minor-aged medical cannabis patients and young adults. There is a need for comprehensive clinical research addressing efficacy, safety, and tailored guidelines specific for pediatric medical cannabis patients. Such insights are pivotal for healthcare providers and policymakers in navigating medical cannabis treatment protocols.

Citing Articles

Use of Cannabis-Based Medical Products for Pediatric Health Conditions: A Systematic Review of the Recent Literature.

Doucette M, Hemraj D, Casarett D, Macfarlan D, Fisher E Med Cannabis Cannabinoids. 2024; 7(1):257-267.

PMID: 39659365 PMC: 11631168. DOI: 10.1159/000542550.

References
1.
Mahabir V, Merchant J, Smith C, Garibaldi A . Medical cannabis use in the United States: a retrospective database study. J Cannabis Res. 2021; 2(1):32. PMC: 7819290. DOI: 10.1186/s42238-020-00038-w. View

2.
Wong S, Wilens T . Medical Cannabinoids in Children and Adolescents: A Systematic Review. Pediatrics. 2017; 140(5). DOI: 10.1542/peds.2017-1818. View

3.
Nutt D, Phillips L, Barnes M, Brander B, Curran H, Fayaz A . A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products. Cannabis Cannabinoid Res. 2021; 7(4):482-500. PMC: 9418467. DOI: 10.1089/can.2020.0129. View

4.
Woo J, van Reekum E, Rosic T, Samaan Z . Children and Youth Who Use Cannabis for Pain Relief: Benefits, Risks, and Perceptions. Adolesc Health Med Ther. 2020; 11:53-61. PMC: 7247732. DOI: 10.2147/AHMT.S254264. View

5.
Silva Junior E, Medeiros W, Torro N, Sousa J, Almeida I, Costa F . Cannabis and cannabinoid use in autism spectrum disorder: a systematic review. Trends Psychiatry Psychother. 2021; 44:e20200149. PMC: 9887656. DOI: 10.47626/2237-6089-2020-0149. View